Published Online
on June 2, 2003

A more recent version of this article appeared on July 1, 2003

This Article Full Text (PDF) All Versions of this Article: 42/1/1    most recent 01.HYP.0000077901.84467.E1v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blann, A. D. Articles by Lip, G. Y.H. Search for Related Content PubMed PubMed Citation Articles by Blann, A. D. Articles by Lip, G. Y.H. Related Collections Cardiovascular Pharmacology Risk Factors Antiplatelets Platelets

Submitted on November 19, 2002
Revised on December 23, 2002

Pharmacological Modulation of Platelet Function in Hypertension

Andrew D. Blann; Sunil Nadar; and Gregory Y.H. Lip^*

From the Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.

^* To whom correspondence should be addressed. E-mail: G.Y.H.LIP{at}bham.ac.uk.

Abstract--Platelets exert a considerable influence on human morbidity and mortality. The rationale for their study in hypertension follows the observation that the major consequences of hypertension are stroke and myocardial infarction. However, the etiology of these consequences in hypertension is, paradoxically, not hemorrhagic (as might be expected from the effects of high blood pressure), but occlusive, with thrombus being the culprit lesion. Mechanisms of platelet activation include high shear force, activation of the renin-angiotensin system, endothelial changes, and the presence of comorbidity, such as atrial fibrillation. The treatment of high blood pressure brings about a reversal of the changes seen in the cell. This could be in part due to the direct effect of the drug on the megakaryocyte and/or the platelets themselves, or it might simply be due to the reduction in blood pressure. Some drugs, such as calcium channel antagonists and angiotensin II receptor blockers, however, might have direct effects on platelet biochemistry other than reducing blood pressure. Finally, antiplatelet drugs are becoming an important part of the management of high-risk hypertensives, which aim to minimize vascular complications.

Key words: platelet activation • hypertension, chronic • antihypertensive therapy

This article has been cited by other articles:

				N. K Hollenberg Spotlight on Renin: Therapeutic opportunities for renin inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 107 - 109. [PDF]

				D. M. Shah Role of the renin-angiotensin system in the pathogenesis of preeclampsia Am J Physiol Renal Physiol, April 1, 2005; 288(4): F614 - F625. [Abstract] [Full Text] [PDF]

				N. D.L. Fisher and N. K. Hollenberg Renin Inhibition: What Are the Therapeutic Opportunities? J. Am. Soc. Nephrol., March 1, 2005; 16(3): 592 - 599. [Abstract] [Full Text] [PDF]

				S. K. Nadar, A. D. Blann, S. Kamath, D. G. Beevers, and G. Y. H. Lip Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) J. Am. Coll. Cardiol., July 21, 2004; 44(2): 415 - 422. [Abstract] [Full Text] [PDF]